Yunkang’s Revenue Proportion from Joint Construction Business for Medical Institution Alliances and Special Testing Items Continue to Grow in 2024
HONG KONG, Mar 31, 2025 – (ACN Newswire via SeaPRwire.com) – Yunkang Group Limited (“Yunkang” or the “Group”; Stock Code: 2325), a leading medical operation services provider in China, has announced its annual results for the year ended December 31, 2024 (the “Reporting Period”). During the year, the Group adhered to its overall business philosophy of “in-depth services and lean operations”, promoted development with innovation, deepened integrated collaboration among “government, industry, academy, research, medicine, application”, accelerated digital application of “AI + medical care”, continuously strengthened refined management, and reduced cost and improved efficiency, demonstrating strong operational resilience.In 2024, due to changes in the macro-environment, intensified competition in the industry as well as its strategic decision to optimize customer structure and product mix, the Group’s performance was temporarily affected. However, relying on its customer-oriented, innovative and coordinated devel…